

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

Pacific Blue(TM) anti-human CD3

RRID:AB_1595437

Type: Antibody

Proper Citation

BioLegend Cat# 300431, RRID:AB_1595437

Antibody Information

URL: http://antibodyregistry.org/AB_1595437

Proper Citation: BioLegend Cat# 300431, RRID:AB_1595437

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Pacific Blue(TM) anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_1595437

Vendor: BioLegend

Catalog Number: 300431

Alternative Catalog Numbers: 300417, 300418, 300442

Record Creation Time: 20250820T034030+0000

Record Last Update: 20250820T165250+0000

Ratings and Alerts

No rating or validation information has been found for Pacific Blue(TM) anti-human CD3.

No alerts have been found for Pacific Blue(TM) anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

McCluskey D, et al. (2025) IgA2+ B cells and IgA2 anti-dsDNA antibodies are selectively targeted by belimumab after rituximab therapy in systemic lupus erythematosus. *Cell reports. Medicine*, 6(8), 102247.

Decker AH, et al. (2025) Interleukin-6 in synovial fluid drives the conversion of DC2s to DC3s in inflammatory arthritis. *iScience*, 28(7), 112957.

Zhao Z, et al. (2025) Sick cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity. *Immunity*, 58(6), 1484.

Arbués A, et al. (2025) Soluble immune mediators orchestrate protective in vitro granulomatous responses across *Mycobacterium tuberculosis* complex lineages. *eLife*, 13.

Kaplonek P, et al. (2023) Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines. *Cell reports. Medicine*, 4(5), 101048.

Abhiraman GC, et al. (2023) A structural blueprint for interleukin-21 signal modulation. *Cell reports*, 42(6), 112657.

Schnizer C, et al. (2022) Persistent humoral and CD4+ TH cell immunity after mild SARS-CoV-2 infection-The CoNAN long-term study. *Frontiers in immunology*, 13, 1095129.

Yen M, et al. (2022) Facile discovery of surrogate cytokine agonists. *Cell*, 185(8), 1414.

Kaplonek P, et al. (2022) mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. *Immunity*, 55(2), 355.

Andreas N, et al. (2022) Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One Vaccination. *Vaccines*, 10(1).

Weymar GHJ, et al. (2022) Distinct gene expression by expanded clones of quiescent memory CD4+ T cells harboring intact latent HIV-1 proviruses. *Cell reports*, 40(10), 111311.

Pullen KM, et al. (2021) Selective functional antibody transfer into the breastmilk after SARS-CoV-2 infection. *Cell reports*, 37(6), 109959.

Alter G, et al. (2020) Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. *Cell*, 183(1), 185.

Leylek R, et al. (2019) Integrated Cross-Species Analysis Identifies a Conserved Transitional Dendritic Cell Population. *Cell reports*, 29(11), 3736.

Alcántara-Hernández M, et al. (2017) High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization. *Immunity*, 47(6), 1037.